Association of Community Cancer Centers to Host Live Online Educational Program on CAR T-Cell Therapy on OMedLive

Share Article

Complementary education for clinicians airing live online and available for on-demand viewing through 2018 about CAR T-cell therapy, its MOA, where it fits into the cancer care landscape, and issues and solutions related to real-world access and coordination-of-care, including availability, cost, and administration.

We are thrilled to partner with PlatformQ Health, and its channel OMedLive, to provide this learning event to help educate the ACCC membership and greater oncology community on the challenges and opportunities presented by immuno-oncology.

CAR T-Cell Therapy for Your Patients: What You Need to Know, will air live online Tuesday, December 5, 2107, from 1:30-2:30 PM EST, featuring Marco L. Davila, MD, PhD, Medical Oncologist with H. Lee Moffitt Cancer Center & Research Institute. Following the live broadcast, the program will be available on OMedLive through December 2018.

“The Association of Community Cancer Centers (ACCC) focuses on the continuing advancement and application of immuno-oncology by providing resources, such as this live educational program on CAR T-cell therapy, to help address evolving operational and programmatic barriers facing the community cancer care team,” said Christian Downs, JD, MHA, ACCC Executive Director. “The U.S. FDA’s recent approval of two CAR T-cell therapies further supports immunotherapy as the fifth pillar of cancer treatment. We are thrilled to partner with PlatformQ Health, and its channel OMedLive, to provide this learning event to help educate the ACCC membership and greater oncology community on the challenges and opportunities presented by immuno-oncology.”

This initial program will focus on the mechanisms of action (MOA) underlying these revolutionary therapies, clinical evidence supporting their use in immuno-oncology, and management of related adverse events. As progress with CAR T-cell therapies accelerates, it’s important for the community cancer care team to understand the real-world access and care coordination issues surrounding these new treatments, including availability, cost, administration, and operational considerations. Through this program, participants will be better able to:

  • Describe the MOA of Chimeric Antigen Receptor T-Cell (CAR-T) therapy and FDA-approved indications
  • Understand where CAR-T therapy might fit into the cancer care landscape and its future applications
  • Recognize access and coordination of care issues and solutions associated with CAR-T therapies including availability, cost, administration and operational considerations

Participants will be able to interact with the program’s presenter, Dr. Davila, on OMedLive during the live broadcast through a live Q&A feature that allows clinicians to submit questions for response in real time. Questions can also be submitted before the live broadcast via a program’s “Q Board” here.

“We are excited to offer the OMedLive platform to ACCC to help further engage and educate community cancer team members around important and emerging topics such as CAR-T,” shared PlatformQ Health CEO, Robert Rosenbloom.

Participants can register for the free online education on OMedLive.

About PlatformQ Health

PlatformQ Health is the leading provider of live, online medical education events, operating 16 therapeutically aligned learning channels dedicated to providing clinicians, patients, caregivers, advocates and administrators rigorous, outcomes-centric education aimed at improving patient care. The company's unique education platform allows participants to connect online from anywhere, to learn about the latest treatments options, and engage in real-time discussion with scientific, research and patient care experts.

About the Association of Community Cancer Centers

The Association of Community Cancer Centers (ACCC) is the premier source of immuno-oncology resources focused on improving operations and processes so that community cancer care teams can provide their patients access to cancer immunotherapies. ACCC empowers the multidisciplinary care team to:

  • Contribute to the advancement of immuno-oncology delivery
  • Build and engage a community of thought leaders in the immuno-oncology field on practice innovations and implementation
  • Provide practical, data-driven resources
  • Support cancer patient access to immunotherapy treatments

ACCC immuno-oncology resources:

  • Monthly eNewsletters that share the latest advances and practical advice for clinicians, fellows, and supportive care staff.
  • Interactive webinars that provide robust discussions on the most relevant topics in immuno-oncology today.
  • An eLearning portal with courses on the real-world application of immunotherapies, including role-specific strategies to optimize patient care, overcome reimbursement challenges, operational approaches for payment, and more.
  • Visiting Experts Programs, one-day, onsite workshops that brings I-O experts directly into community cancer programs to provide multidisciplinary learning on the nuances of immuno-oncology
  • Diverse tumor toolkits, curated by tumor-specific subcommittees, comprised of experts in immunotherapy delivery, which addresses biomarkers and combination therapies, supportive care components, and reimbursement issues related to specific tumor-types.
  • Publications that delve into the latest advances in immunotherapy treatments.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lauren Alford
@OMedLive
since: 12/2012
Follow >
Visit website